Home › Funds › Anchorage Capital Group, L.L.C. › DNA
Anchorage Capital Group, L.L.C. position in DNA
GINKGO BIOWORKS HOLDINGS INC · Health Care
Anchorage Capital Group, L.L.C. reported holding 1,746,363 shares of DNA (GINKGO BIOWORKS HOLDINGS INC) in its Q2 2026 13F filing — a position valued at US$17.3M, representing 3.84% of its reported portfolio and ranking #3 among its reported holdings. Anchorage Capital Group, L.L.C. has disclosed DNA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Anchorage Capital Group, L.L.C.'s DNA position evolved
Anchorage Capital Group, L.L.C. first disclosed a stake in DNA in Q3 2023 at 69,854,593 shares (US$126.4M). Across 12 filings, Anchorage Capital Group, L.L.C. increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 10 time(s). The most recent filing (Q2 2026) shows 1,746,363 shares valued at US$17.3M. Notable position changes include a 98% trim in Q3 2024 (shares rose 20% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 69.85M | $126.44M | New |
| Q4 2023 | 69.85M | $118.05M | Hold |
| Q1 2024 | 69.85M | $81.03M | Hold |
| Q2 2024 | 69.85M | $23.35M | Hold |
| Q3 2024 | 1.75M | $14.23M | Reduce |
| Q4 2024 | 1.75M | $17.15M | Hold |
| Q1 2025 | 1.75M | $9.95M | Hold |
| Q2 2025 | 1.75M | $19.65M | Hold |
| Q3 2025 | 1.75M | $25.46M | Hold |
| Q4 2025 | 1.75M | $14.51M | Hold |
| Q1 2026 | 1.75M | $10.71M | Hold |
| Q2 2026 | 1.75M | $17.31M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DNA and 13F data
DNA (GINKGO BIOWORKS HOLDINGS INC) is a Health Care company. 32 other funds we track also report a position in DNA — the largest reported positions include FORBES J M & CO LLP (US$12.5M), SB INVESTMENT ADVISERS (UK) LTD (US$6.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DNA
- FORBES J M & CO LLP 977.37K sh · $12.54M · Q3 2026
- SB INVESTMENT ADVISERS (UK) LTD 610.73K sh · $6.05M · Q2 2026
More on Anchorage Capital Group, L.L.C.
FAQ
How long has Anchorage Capital Group, L.L.C. held DNA?
Anchorage Capital Group, L.L.C. has disclosed DNA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Anchorage Capital Group, L.L.C.'s current position in DNA?
As of Q2 2026, Anchorage Capital Group, L.L.C. holds 1.75M shares of DNA (GINKGO BIOWORKS HOLDINGS INC), valued at $17.31M, representing 3.84% of its reported portfolio and ranking #3.
Has Anchorage Capital Group, L.L.C. been buying or selling DNA?
In the latest 13F filing (Q2 2026), Anchorage Capital Group, L.L.C. held unchanged its position in DNA.
Which other funds hold DNA?
Other major institutional holders of DNA include FORBES J M & CO LLP, SB INVESTMENT ADVISERS (UK) LTD, among 32 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.